Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Sublingual or intramuscular forms may be considered for patients with documented deficiency or absorption issues
Upregulation of efflux transporters such as MDR1 (ABCB1) has been shown to mediate cross-resistance to chemotherapeutics and targeted agents, including paclitaxel and olaparib, in ovarian cancer
Melanie Avalon Fine-tuned
Slow Responders (15-20% of users): May not notice meaningful changes until week 3 or 4, with peak benefit reached around week 8 to 10
US$ 23.19
US$ 24.39
US$ 28.20
US$ 20.62
